Paper25534129
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N and 21 others. Lung Cancer, 2015. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Papers, record 25534129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25534129
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Radiotherapy | Major topic |
| Adult | |
| Aged | |
| Chemoradiotherapy | |
| Cisplatin | |
| Disease Progression | |
| Drug Combinations | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Neoplasm Staging | |
| Oxonic Acid | |
| Radiotherapy Dosage | |
| Retreatment | |
| Survival Analysis | |
| Tegafur | |
| Treatment Outcome |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41099317 | Acute Radiation Esophagitis After Chemoradiotherapy Demonstrating "Tube-Like" FDG Uptake on PET-CT: Case Report and Literature Review. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/41099317 | PubMed |
| 40837011 | A phase I study of S-1 and cisplatin with concurrent hypofractionated carbon-ion radiotherapy for patients with stage III non-small cell lung cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/40837011 | PubMed |
| 39910007 | Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/39910007 | PubMed |
| 37781162 | Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/37781162 | PubMed |
| 36570411 | A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/36570411 | PubMed |
| 35923924 | Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/35923924 | PubMed |
| 35869676 | Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study. | Thorac Cancer | 2022 | https://conductscience.org/library/papers/35869676 | PubMed |
| 35000608 | Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data. | BMC Pulm Med | 2022 | https://conductscience.org/library/papers/35000608 | PubMed |
| 33717228 | A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). | Ther Adv Med Oncol | 2021 | https://conductscience.org/library/papers/33717228 | PubMed |
| 33319495 | Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. | Cancer Med | 2021 | https://conductscience.org/library/papers/33319495 | PubMed |
| 32675194 | Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32675194 | PubMed |
| 32099495 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. | Lung Cancer (Auckl) | 2019 | https://conductscience.org/library/papers/32099495 | PubMed |
| 32020735 | S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32020735 | PubMed |
| 30673966 | Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer. | Gen Thorac Cardiovasc Surg | 2019 | https://conductscience.org/library/papers/30673966 | PubMed |
| 30655791 | ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. | Oncol Lett | 2019 | https://conductscience.org/library/papers/30655791 | PubMed |
| 30206369 | A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. | Br J Cancer | 2018 | https://conductscience.org/library/papers/30206369 | PubMed |
| 29642202 | S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/29642202 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25534129
GET https://conductscience.org/api/papers/v1/25534129/authors?page=2